CD33 and central nervous system cancer: According to the recent hypothesis, glioma immune escape is facilitated by inhibitory CD33-related Siglecs that interact with sialic acid on malignant cells and trigger a reduced activation response, resulting in an improved survival of glioma cells [53,54,55,56].